Please ensure Javascript is enabled for purposes of website accessibility

CVS's Prescription for Competition

By Phil Wohl – Updated Nov 16, 2016 at 4:52PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The national drugstore chain is looking to take advantage of increased size.

When I was a kid the drugstores were nothing like they are today. As a kid trailing my parents around, it was pure boredom. There was nothing in the store to look at besides creams, pills, sprays, and that dreaded corner with a wheelchair and crutches.

Fast-forward to the drugstores of today, which have bright lights and aisles and aisles of cool stuff. Food, magazines, office and school supplies, home items, photo processing, and even toys and sporting goods have become part of the store mix. The drugstore has effectively bridged the gap among the 24-hour convenience store, the grocery store, and the old 5 and Dime stores.

So much has changed in the drugstore industry, but the one constant has always been customer service. CVS (NYSE:CVS), which is now the leading drugstore chain following the recent acquisition of Eckerd from J.C. Penney (NYSE:JCP), now has the size to leverage its costs more effectively. With pressure from competitors such as Rite Aid (NYSE:RAD) and Walgreen (NYSE:WAG), and national discount retail chains with drug counters such as Wal-Mart (NYSE:WMT) and Target (NYSE:TGT), CVS made a smart move to get bigger and stronger (without sacrificing customer service). The integration of Eckerd should take about a year as the company closes underperforming stores in order to gain additional cost synergies.

Additionally, the company recently reported better-than-expected second-quarter earnings of $0.56 per share, which beat the consensus estimate of $0.54 and last year's earnings of $0.49 a share. The company credited its non-pharmacy sales with a major chunk of the improvement, proving that people are shopping for much more than their health in drugstores.

The company has taken a chance through its acquisition of struggling Eckerd, but I think the gamble will pay off. CVS shares, which are trading at 16 times the consensus 2005 estimate of $2.61 per share, appear to be relatively inexpensive when compared with the 24% growth that is expected next year. Competition might be the name of the game in the drugstore industry, but CVS appears to have written the right prescription.

Fool contributor Phil Wohl spent more than 12 years on Wall Street and now concentrates his writing on more fictional characters. He has no stake in any firm mentioned above.

None

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Walmart Stock Quote
Walmart
WMT
$130.06 (-2.50%) $-3.33
Target Corporation Stock Quote
Target Corporation
TGT
$152.61 (-0.23%) $0.35
CVS Health Corporation Stock Quote
CVS Health Corporation
CVS
$98.35 (-1.48%) $-1.48
Walgreens Boots Alliance, Inc. Stock Quote
Walgreens Boots Alliance, Inc.
WBA
$32.83 (-1.47%) $0.49
J. C. Penney Company, Inc. Stock Quote
J. C. Penney Company, Inc.
JCPN.Q
Rite Aid Corporation Stock Quote
Rite Aid Corporation
RAD
$7.01 (-0.99%) $0.07

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
339%
 
S&P 500 Returns
109%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.